As to which treatment strategy is the best for the patients with major EGFR-mutation positive NSCLC, recently, the highly anticipated findings of the phase III FLAURA trial showed 38.6 months of overall survival (OS) with frontline osimertinib, a 3G EGFR-TKI, versus 31.8 months with erlotinib or gefitinib [6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.